NCT03383367

Brief Summary

France is one of the European countries where the incidence of colorectal cancer is the highest among cancers for both sexes. Fecal occult blood screening has been implemented since 2008. However, this screening excludes high risk people who have a 10 to 30 % risk of developing a CRC during their lifetime. Colonoscopy follow up of these persons is not organized, and it is up to the attending physician to recall the date of the surveillance colonoscopy. This results in a poor compliance with the recommendations by these people. A postal reminder of the surveillance colonoscopies sent by The French screening organizations to the patients should increase adherence to follow-up recommendations. The colorectal cancer screening organizations will collects from the hepatogastroenterologists (HGE) informations on colonoscopies of people more than 50 years old who live in the Rhone. These informations will allow to send a reminder 3 months before the date recommended by the HGE. Participation rate and timeliness will be assessed, as well as the severity of the lesions found. A medico-economic analysis will also be carried out.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
33,000

participants targeted

Target at P75+ for not_applicable colorectal-cancer

Timeline
Completed

Started Aug 2017

Shorter than P25 for not_applicable colorectal-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 24, 2017

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

December 1, 2017

Completed
25 days until next milestone

First Posted

Study publicly available on registry

December 26, 2017

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

December 26, 2017

Status Verified

December 1, 2017

Enrollment Period

1.2 years

First QC Date

December 1, 2017

Last Update Submit

December 22, 2017

Conditions

Keywords

mass screeningcolonoscopy surveillancehigh risk patients

Outcome Measures

Primary Outcomes (1)

  • participation rate at future colonoscopy

    participation rate at future colonoscopy that is the number of patient that really have colonoscopy among the patients who receive a reminder letter The systematic registry of colonoscopies will permit to assess if a patient performs it.

    At time of evaluation we will check the colonoscopy realized at six months after sending the letter at the person

Secondary Outcomes (2)

  • description of lesions severities found at surveillance colonoscopy after letter reminder

    Lesions'severity will be evaluated at 6, 9 or 15 months following the reminder sent according to the colonoscopist's recommendation (1,3 or 5 years after reference exams). By the way of systematic registration. .

  • Cost-utility analysis of the reminder letter for surveillance colonoscopy

    Lesions'severity will be evaluated at 6, 9 or 15 months following the reminder sent according to the colonoscopist's recommendation (1,3 or 5 years after reference exams). The costs will be registered at the same time.

Study Arms (1)

Tempo Colo

EXPERIMENTAL
Behavioral: Tempo Colo

Interventions

Tempo ColoBEHAVIORAL

Reminder letter for people at high risk of colorectal cancer.

Tempo Colo

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • people aged 50 years or more ;
  • at high risk of colorectal cancer ;
  • living in Rhône administrative departement or Metropolitan Lyon

You may not qualify if:

  • person with chronic inflammatory bowel disease
  • colorectal cancer in diagnosis or treatment period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Adémas-69

Lyon, Rhône, 69005, France

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Model Details: A prospective interventional study to evaluate the impact of a reminder sent by the Adémas-69 organization to improve coloscopy surveillance and compliance with recommendations for high risk of colorectal cancer people.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 1, 2017

First Posted

December 26, 2017

Study Start

August 24, 2017

Primary Completion

November 1, 2018

Study Completion

December 1, 2018

Last Updated

December 26, 2017

Record last verified: 2017-12

Locations